joins us with that story. And what's new, Steve. >> Hey there Mike.Yeah, I'm here in Brooklyn, New York. This is where Samsung is unveiling those two new phones. You talked about the Galaxy Flip and Fold seven, the seventh generation of those phones, foldable devices.They're cool. They're fun to talk about, not big sellers. But what we're really here to talk about is the artificial intelligence features in here, and how Samsung is approaching it versus other competitors here.This is Apple's biggest competit ...

【环球网财经综合报道】知名ETF发行商Roundhill Investments又有新动作，推出一只独特的美股基金——"S&P 500 No Dividend Target ETF"（标普500无股 息目标ETF，代码：XDIV），计划于7月10日（本周四）面市。 Roundhill向来以创新ETF著称，2023年推出的Magnificant Seven ETF（MAGS）获ETF.com"最佳新ETF"称号，去年还推出"中国龙"ETF（DRAG）。此次新 基金目标明确且具战略意义，旨在追踪标普500指数表现的同时规避派息，通过在股息日前出售标的，让持有人无法获得股息，进而规避相关税负。 XDIV是近期市场众多"税务优化型"产品之一，LionShares、F/m Investments等也推出类似ETF。资深ETF专家Dave Nadig称该策略"非常明智"，ETF分析师 Athanasios Psarofagis表示，避开资本利得税能力正成为ETF核心卖点，发行商利用优势渐成趋势。（陈十一） 当前，标普500指数及相关ETF整体走强，资产管理公司纷纷聚焦减少应税事件的产品。Roundhill首席执行官Dav ...

Core Insights - Novo Nordisk (NVO) has achieved significant growth driven by the success of its semaglutide-based therapies, Wegovy and Ozempic, while also diversifying into rare blood disorders [1][9] Product Portfolio - Key marketed hemophilia therapies include NovoSeven and Esperoct, contributing incremental revenues [2] - Alhemo has recently been approved in the EU for hemophilia A or B with inhibitors, although it is not yet approved in the U.S. [3] - The company is evaluating Mim8 in a late-stage program for hemophilia A, with regulatory submission anticipated in 2025 [4] Competitive Landscape - Eli Lilly (LLY) generates substantial revenue from its tirzepatide medicines and has a diverse product range across various therapeutic areas, including oncology and immunology [5] - Merck (MRK) is also expanding its therapeutic reach beyond its flagship oncology drug Keytruda, with new products expected to generate significant long-term revenues [6] Stock Performance and Valuation - Year-to-date, Novo Nordisk shares have declined by 19.6%, underperforming the industry and the S&P 500 [7][8] - The company's shares trade at a forward price/earnings ratio of 16.31, higher than the industry average of 15.09, but below its five-year mean of 29.25 [10] Earnings Estimates - Earnings estimates for 2025 have improved from $3.89 to $3.93 per share, while 2026 estimates have decreased from $4.76 to $4.58 [15] - The stock's return on equity is 80.95%, significantly higher than the industry average of 33.55% [18]

11天里，40位中外导演在15个剧场空间带来94场演出，戏剧节"情感和理智"的主题出现在阿那亚的街头巷尾。戏 剧的存在本就是情感与理智的交织，情感是冲动与狂欢，理智是知识与克制，两者的纠缠融合，恰是戏剧节的样 貌。今年的阿那亚戏剧节，依然呈现出一场海边潮流戏剧的全景，从现代舞到荒诞剧，从肢体、人偶、声音、材 料甚至机器人戏剧，当代戏剧千姿百态的样貌被全方位探索并打开，浪潮般涌向观众。 在海的波浪与宁静之中，在众人的欢呼与尖叫声中，夜空中的海上烟花渐次绽放，候鸟300的倒计时牌走到终点， 第五届阿那亚戏剧节在6月29日宣告落幕。 这片北方之海不像南方海滩那么甜美宁静，它的阴晴不定与力量感，给戏剧增添了大自然的风雨、雷鸣，也成为 国内青年文化一年一度的精神充电站。 法国北方剧院艺术总监大卫·博贝执导的开幕大戏《唐璜》，在海边架起巨型雕像，演员围绕雕像诠释莫里哀经典 巨作。闭幕大戏则是法国编舞家玛姬·玛汉以贝克特作品为灵感创作的《五月May B》，被视为舞蹈史中教科书级 的作品。另一部闭幕戏来自比利时OG剧团的《谢谢谢谢》，用影像、声音和幽默献给观众一场游戏通关庆典，探 讨生活的本质。 "我们邀请世界各地的戏剧人来 ...

一楼（建议谨慎购买）： 一楼房价低廉，出行方便，是其吸引人的两大优点。然而，其缺陷不容忽视：采光差，日光照射时间短，白天需常开灯；私密性 差，容易受到外界窥视，需长期拉窗帘；潮湿问题突出，地板需频繁更换；易受地面噪音干扰，尤其临街一楼；夏季蚊虫滋扰严重，需常闭门窗。综合考 量，一楼的诸多不足使其成为购房时需谨慎考虑的选择。 二楼： 二楼房价通常低于三至五楼，老年人出行也较为方便，且不像一楼那样潮湿。然而，二楼采光和视野相对较弱。更需注意的是，部分楼房二楼存在 下水道反涌问题，夏季尤为严重，臭气熏天，尽管现在开发商多能解决此问题，但仍需谨慎考察。 五至六楼： 视野开阔，采光通风良好，是五至六楼的显著优势。然而，在没有电梯的情况下，高龄老人上下楼十分不便。此外，高楼层在转售时也可能面 临较大的难度，寻找买家相对困难。尽管购房时价格可能较低，但未来转售的潜在风险不容忽视。 准备购房？七层以下的多层住宅，楼层选择至关重要。坊间流传着诸多说法，例如四楼不吉利，但事实并非如此。本文将深入探讨七层以下各楼层的优劣， 助您做出明智选择。 顶层（建议谨慎购买）： 顶层住房拥有极佳的视野和采光，私密性也更好，价格通常相对较低。然 ...

MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd., “Norwegian Cruise Line Holdings” or the “Company”) announced that it has successfully upsized its existing senior secured revolving credit facility from $1.7 billion to $2.486 billion, with the existing terms and maturity date of 2030 unchanged. “The upsizing of our revolving credit facility significantly enhances our liquidity, representing another key step in further optimizing ou ...

Dining Rooms Across All 16 Ships, Including 15 Main Dining Rooms and the Sanctuary Collection Restaurant on Sun Princess, Recognized for Outstanding Wine ListsFORT LAUDERDALE, Fla., June 26, 2025 /PRNewswire/ -- Princess Cruises is once again raising a glass to excellence, as all 16 ships in its fleet have earned the prestigious Wine Spectator Award of Excellence in the publication's 2025 Restaurant Awards. Now a two-time winner, 15 Princess main dining rooms were recognized, alongside the Sanctuary Collect ...

Three Part Advisors East Coast IDEAS Conference June 12, 2025 Forward-Looking Statements This Presentation ( the "Presentation"), contain forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historica ...

17 June 2025 | 8:13PM HKT Laopu Gold (6181.HK) Buy Raise TP on stronger growth outlook; Expanding Moat/TAM through new products, VIC, ornaments; An eventful quarter ahead; Reiterate Buy 6181.HK 12m Price Target: HK$1,090.00 Price: HK$881.50 Upside: 23.7% We raise Laopu Gold's 12m TP to HKD1,090 to reflect our upwards revision to earnings by 15-26% in 2025-27E due to stronger YTD tracking in both online/offline sales and faster store expansion backed by rising brand awareness and a continued gold price uptre ...

Summary of Spyre Therapeutics Inc (SYRE) Update / Briefing June 17, 2025 Company Overview - **Company**: Spyre Therapeutics Inc (SYRE) - **Focus**: Development of next-generation anti-TL1A antibodies for inflammatory bowel disease (IBD) and rheumatologic diseases Key Points and Arguments Phase I Clinical Trial Results - Positive interim results for two anti-TL1A molecules (SPY-two and SPY-seventy two) were announced, indicating favorable safety profiles and complete target engagement at low doses [2][5][21] - Both molecules demonstrated a half-life of approximately 75 days for SPY-two, supporting quarterly or biannual dosing [16][21] - The trials showed low rates of adverse events, with no serious adverse events reported [14][21] Phase II Development Plans - Plans to advance SPY-two into the Skyline UC study and SPY-seventy two into the Skyway RD study [22][31] - The Skyline UC study will explore safety and efficacy of three long-acting monotherapies and three combination therapies in ulcerative colitis [5][10] - The Skyway RD study will evaluate SPY-seventy two in three rheumatologic diseases, leveraging a basket design for efficiency [31][32] Market Potential and Value Creation - The development plan targets markets with over $60 billion in annual revenue, with multiple paths to substantial value creation [11] - The company aims to address unmet needs in IBD and rheumatologic diseases, potentially transforming treatment paradigms with innovative therapies [6][28] Study Design and Efficiency - The innovative platform and basket designs of the studies are expected to provide 35% to 40% cost savings compared to separate studies [10][33] - The Skyline UC study is designed to require 40% fewer patients, enhancing operational efficiency [26][27] Immunogenicity and Safety - Ongoing analysis of anti-drug antibodies (ADA) shows no apparent impact on pharmacokinetics (PK) or pharmacodynamics (PD) [60][92] - The company believes its combination therapies will have superior safety profiles compared to existing treatments, particularly those with known safety issues [61][82] Future Catalysts - Anticipated readouts include open-label results from the Skyline UC study in 2026 and placebo-controlled results for SPY-seventy two in 2026 [39][80] - The company is well-funded to execute its studies, with a cash runway extending into the second half of 2028 [39] Additional Important Content - The company emphasizes the potential for its anti-TL1A antibodies to provide improved options for patients and physicians, with a focus on both efficacy and convenience [6][28] - The design of the studies is patient-centric, aiming to reduce operational complexity and enhance patient recruitment [27][28] - The company is exploring the role of TL1A in rheumatologic diseases, supported by preclinical evidence of its efficacy [31][36] This summary captures the essential information from the conference call, highlighting the company's strategic direction, clinical trial results, and future plans.